Updates are available Correction dated 2024-11-07
Click to view Correction: https://doi.org/10.1038/s41598-024-77057-7
-
Authors
Luthi-Carter, Ruth
Cappelli, Sara
Le Roux-Bourdieu, Morgan
Tentillier, Noemie
Quinn, James P.
Petrozziello, Tiziana
Gopalakrishnan, Lathika
Sethi, Purva
Choudhary, Himanshi
Bartolini, Giorgia
Gebara, Elias
Stuani, Cristiana
Font, Laure
An, Jiyan
Ortega, Vanessa
Sage, Jessica
Kosa, Edina
Trombetta, Bianca A.
Simeone, Roberto
Seredenina, Tamara
Afroz, Tariq
Berry, James D.
Arnold, Steven E.
Carlyle, Becky C.
Adolfsson, Oskar
Sadri-Vakili, Ghazaleh
Buratti, Emanuele
Bowser, Robert
Agbas, Abdulbaki
-
Funding
Funding for this research was provided by:
Target ALS Foundation (BB-2022-C5, Industry-Led Consortium Project Grant)
NOSRESCUEALS
alsfindingacure
- License Information
-
More Information
Article History
Received: 24 October 2023
Accepted: 21 August 2024
First Online: 18 September 2024
Change Date: 7 November 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-024-77057-7
Competing interests
: RLC, MLRB, LF, GB, OA, TS, TA, MKV and AP are employees of AC Immune and are entitled to stock options. NT and EG are former employees of AC Immune. RB and JA have stock options in nVector, Inc., a company developing biomarker assays for neurologic diseases. EB is a member of the Scientific Advisory Board of VectorY. SEA has served on scientific advisory panels or consulted with Allyx Therapeutics, BioVie, Daewoong Pharmaceutical, EIP Pharma, Quince Therapeutics, Jocasta, NeuroSense, Risen Pharmaceutical, Sage Therapeutics, and Vandria. All other authors declare that they have no competing interests.
